INTAXEL

INTAXEL (Paclitaxel USP) 6mg/ml Injection

Features

INTAXEL (Paclitaxel) is a mitotic inhibitor.

ATC-Code: L01CD01

Mechanism of action:

INTAXEL (Paclitaxel USP) is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, INTAXEL (Paclitaxel USP) induces abnormal arrays or “bundles” of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.

Therapeutic Indications

INTAXEL (Paclitaxel) is indicated:

  • As first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, INTAXEL is indicated in combination with cisplatin.
     
  • For the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy
     
  • For the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
     
  • In combination with cisplatin, for first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy
     
  • For the second-line treatment of AIDS-related Kaposi’s sarcoma

Presentation

Strength is denoted by disposable cap colour. 

Strength

Packaging

Pack Size*
30 mg/5 ml 5ml clear glass vial 1
100 mg/16.7 ml 20ml clear glass vial 1
150 mg/25 ml 25ml clear glass vial 1
300 mg/50 ml 50ml clear glass bottle 1
600 mg/100 ml 100ml clear glass bottle 1

* Not all pack sizes may be marketed or available locally.
* Product images are for illustration purposes only. 

 

Product Information

​Please note that this product may not be available in all countries due to different registration status. Additionally, approved indications, contraindications, side effects, warnings and all other product characteristics may differ between countries.

If you require any information, please contact your local organization.